

GRANT LETTER OF AGREEMENT (the "Agreement") No. 18431-P-FEL

Statement of Purpose

Fondazione IRCCS Istituto Neurologico Carlo Besta ("Applicant") has submitted a grant request application to Biogen MA, Inc. ("Biogen"), (each a "Party" and together the "Parties") to seek funding for the project entitled, "Diagnosis and management of adult patients with neuromuscular diseases" ("Project") to begin on July 31, 2021 by the Applicant, as further described in the Grant request ID# 18431-P-FEL ("Grant Application").

Grant Award

Biogen hereby awards this grant of **EUR 48,780.00** ("Grant") to the Applicant to be used as follows:

Biogen agrees to provide the Applicant a lump sum of **EUR 48,780.00** as a grant for the use described more fully in the Grant Application.

The amount of the Grant is based on a budget provided to Biogen in the Grant Application and is based on a good faith estimate of the actual costs of the Project.

The Parties acknowledge and agree that this Grant is not being given in exchange for any explicit or implicit agreement to purchase, prescribe, recommend, influence, or provide favorable formulary status for any Biogen product. The amount of the Grant has not been determined in a manner that takes into account the volume or value of referrals.

Independence

The Applicant must ensure that all decisions regarding the identification of Project needs, determination of objectives, selection of methods, selection and development of content, and the selection of service providers or personnel, speakers, moderators, chairpersons, planning committee personnel (herein referred to collectively as "Faculty"), and all other persons in a position to control the design and execution of the Project are independent of any commercial influence or bias. Neither Biogen nor its affiliates, distributors or agents shall direct the design or execution of the Project. The Applicant will independently make the selection of the Faculty for the Project.

Disclosure of Financial Relationships and Program Funding Support

The Applicant will ensure meaningful disclosure to the audience prior to the beginning of the Project of: 1) Biogen funding of the Project, without mention of product trade names or product messages; and, 2) any significant relationship between the Applicant and Biogen, and/or between individual Faculty and Biogen. For individuals with no relevant financial relationships, the audience must be informed that no relevant financial relationships exist. In addition, the Applicant shall acknowledge support from Biogen in program brochures, syllabi, and other Project materials, without any use of Biogen logo(s).

Promotional Activities

No promotional activities will be permitted at the same time or in the same room or obligate path as the Project. Arrangement for commercial exhibits or advertisements will not influence planning or interfere with the Project, nor will they be a condition of the provision of commercial support for the Project. The nature and scheduling of any social event or meal held in connection with the Project is at the sole discretion of the Applicant. The Applicant agrees to ensure that any social event or meal held in connection with the Project is modest, does not compete with, nor take precedence over, the Project.

Objectivity & Balance



The Applicant will make every effort to ensure, if applicable, that the Project is non-promotional and any references to pharmaceutical products, including Biogen's products, are objectively selected and presented with a balanced view that is without commercial bias for or against such products. The Applicant shall use generic names for all products discussed in connection with the Project. The title of the Project shall adequately reflect the purpose, content, and scope of the Project. The Project shall include discussion of multiple treatment options and will not focus on a single product or regimen unless existing treatment options are so limited as to preclude any meaningful discussion of alternative therapies.

Limitations on Data and Discussion of Unapproved Uses

The Applicant will ensure that the Project provide truthful and non-misleading information according to local regulations, including meaningful disclosure of limitations on data (e.g., ongoing research, interim analyses, preliminary data, or unsupported opinion). The Applicant will require that Faculty disclose when a product is not approved in the host country for the use under discussion.

Audience Selection and Opportunities for Debate

The audience for the Project will not be selected by any Biogen representative, or reflect Biogen's sales or marketing goals. The Applicant will ensure meaningful opportunities for questioning and scientific debate.

Enduring Materials

Biogen will not distribute any enduring materials (e.g., printed, recorded, or computer-based materials) that are developed through support of this Project. Requests from healthcare professionals for information regarding this Project will be forwarded to the Applicant, and the Applicant will be responsible for dissemination of any enduring materials relating to this Project.

Use of Contributed Funds

Funds will be in the form of a Grant made payable to the Applicant or the Applicant's designee. The Applicant must make all decisions regarding the disposition and disbursement of Biogen support hereunder, and no additional funds outside those noted in the Grant Application will be provided by Biogen to the Applicant. Biogen may, at its discretion, require the Applicant to provide written documentation regarding accounting of the funds awarded by Biogen for the Project as well as full reconciliation of Grant. Failure of the Applicant to meet any conditions or contingencies in the Grant Application, this Agreement or which have otherwise been communicated by Biogen may render this Agreement null and void.

The Applicant may collect additional funds from third parties for the Project under the obligation that the collected funds will not be in excess of the anticipated total costs of the Project. The Applicant confirms that the Grant does not overlap with regular financing of its activities from any public institution or governmental authority, and with financial support received by other third parties. The Applicant furthermore acknowledges that the Grant will not be used to finance any research activities that involve Biogen products or medicinal products from other companies, nor any other Investigator Initiated/Sponsored Trials. The Applicant warrants that the Grant shall not be used to finance any activities related to hospitality, gifts, or payments for HCP educational event related costs (e.g. congress attendance) unless explicitly set forth and detailed within Grant Application.

Compliance with Applicable Standards

The Applicant will comply with and assure that all Applicant contractors comply with all relevant requirements of: 1) the U.S. Food and Drug Administration Final Guidance on Industry-Supported Scientific and Educational Activities; 2) the American Medical Association Guidelines on Gifts to Physicians (Opinion 8.061 and all clarifying addendums) and Continuing Medical Education (Opinion 9.011); 3) PhRMA Code on Interactions with Healthcare Professionals; 4) Office of the Inspector General guidance, including the Compliance Program Guidance for Pharmaceutical Manufacturers; 5) the U.S. Federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b and any similar anti-kickback laws,



or the corresponding provisions of any future laws and the United States Foreign Corrupt Practices Act, the UK Bribery Act 2010 and the OECD Convention on Combatting Bribery of Foreign Public Officials in International Business Transactions and 6) all other similar and applicable laws and regulations in the country of the Applicant's registered seat and 7) all other relevant standards and guidelines.

The Applicant represents and warrants to Biogen that any payment to contractors or other agents working on behalf of Applicant as part of the Project (i) represents the fair market value, (ii) is not offered or provided, in whole or in part, with the intent of, directly or indirectly, implicitly or explicitly, influencing or encouraging the recipient to purchase, prescribe, refer, sell, arrange for the purchase or sale, or recommend favorable formulary placement of a Biogen product or as a reward for past behavior, and (iii) is in compliance with all applicable laws and regulations, including the local laws and regulations of the country of the recipient.

Biogen will not be responsible from any deviation from relevant standards that is not the direct fault of Biogen. Biogen hereby acknowledges that it has no ownership of the Project.

Firewalls

The Applicant has disclosed all relevant information concerning its current and previous relationships, financial and otherwise, with Biogen, as well as those of any of its contractors, as part of the proposal submitted to Biogen in support of this Grant. To the extent applicable, the Applicant certifies that for each organization, an appropriate separation exists between the part of the organization that provides marketing or promotional services to Biogen and the part of the organization receiving the Grant.

Excluded Individuals/Entities

The Applicant noted hereby certifies that to the best of its knowledge, none of its employees or subcontractors is on the Office of Inspector General's List of Excluded Individuals/Entities or has been debarred, excluded, or is otherwise ineligible to participate in Federal healthcare programs.

Provider Responsibilities

In the event that Applicant is unable to carry out the Project as fully described in the Grant Application, including changes to the (a) date(s), (b) scope, and/or (c) method of delivering the Project, etc. Applicant shall notify Biogen immediately and provide a detailed explanation, in writing, of the reason(s) for such change. Any changes must be approved by Biogen prior to implementation. Any changes that occur without prior notification will constitute a breach of this Agreement and may render the Applicant ineligible to receive future grants or other funding from Biogen.

Confidentiality

The Parties anticipate that under this Agreement it may be necessary for one Party to transfer to the other Party information of a confidential or proprietary nature ("Confidential Information"). As such, all such transfers and disclosures of information shall be governed by the confidentiality and non-disclosure provisions hereunder. The Parties agree that the existence and terms of this Agreement shall be deemed Confidential Information and, as such, shall not be disclosed to any third party without both Parties' prior express written consent, or as required by law.

As used in this Agreement, the term "Confidential Information" shall mean all trade secrets or confidential or proprietary information provided by either Party, or one of its representatives, to the other, or its representatives.

Confidential Information does not include information that: (1) is approved for release by the written authorization of the non-disclosing Party; (2) the disclosing Party can show was already in its possession at the time of disclosure; (3) is or becomes publicly available by other than unauthorized disclosure by the disclosing Party; (4) is received by the disclosing Party from a third party who is rightfully in possession of such information free of any obligation to maintain its confidentiality; or (5) is independently developed by an employee, agent, or contractor of



the disclosing Party without access to the Confidential Information.

The Parties agree that, except as required by judicial order or governmental laws or regulations, the Confidential Information of Biogen shall be used by Applicant solely for the purpose of fulfilling any responsibilities agreed to by the Parties under the terms of this Agreement. Each Party agrees to hold the Confidential Information of the other Party in confidence by security measures, devices, and procedures equal to those used by it in securing its own confidential documents. The Parties further agree that the Confidential Information of Biogen shall be disclosed only to those officers, employees, and representatives of Applicant who need to know such Confidential Information for the purposes of fulfilling any responsibilities agreed to by the Parties under the terms of this Agreement; it being understood that such officers, employees, and representatives shall be bound by the terms of this Agreement and Applicant shall be liable for any breaches by its officers, employees, and representatives.

Liability

Biogen shall not be liable for any loss, injury, or damage incurred by Applicant or by a third party as a result of activities funded under the Project, including any loss, injury, or damage resulting from a negligent or willful act or omission by Applicant. Applicant shall indemnify and hold Biogen harmless from any liability, loss, cost, and expense (including, but not limited to, attorneys' fees and costs) incurred by Biogen as a result of Applicant's negligent or willful act or omission.

Disclosures/Reporting

The Parties acknowledge and agree that Biogen may have certain disclosure and reporting obligations pursuant to applicable federal and state laws and regulations and institutional policies, including, without limitation, the disclosure/reporting of the Grant, and Applicant hereby authorizes Biogen to make such disclosures. Upon Biogen's request, Applicant may be asked to complete and submit to Biogen, interim and final progress or status reports, final budget reconciliation, and transparency reporting information for the Project. Applicant agrees to fully cooperate with Biogen to ensure that Biogen can meet its reporting obligations in a timely manner.

As a member of the European Federation of Pharmaceutical Industries and Associations ("EFPIA") and of science industries, the codes adopted by the EFPIA and science industries, including the Swiss Pharma-Kooperations-Kodex (Pharmaceutical Cooperation Code) (Internet link: <u>www.scienceindustries.ch</u>), apply to Biogen as to many other pharmaceutical companies. These oblige the participating companies to publish on their publicly accessible company web-sites payments in kind as defined in the above codes. To comply with these obligations, Biogen will collect, record and publish information concerning payments in kind to the Applicant in accordance with the following principles.

"Payments in kind" are defined as every direct or indirect transfer of value in cash or in kind or by other means, that can be allocated to the following categories according to the Pharma-Kooperations-Kodex: donations and grants, funding research and development, including but not limited to studies, clinical studies and non-interventional studies, non-monetary benefits in connection with participation in medical training and conferences, including participation/registration fees, sponsorship contracts and travel and subsistence expenses, service and consultancy fees and other payments in kind.

In particular, but not exclusively, the following data is specified as "information" according to the Pharma-Kooperations-Kodex: the sums granted, names and business addresses of the professionals and/or organizations in the health care system, type of non-monetary benefits, the respective reporting periods and the grounds for/purposes of the grant of monetary advantages.

Publication is per calendar year (for the first time in 2016 for payments in kind made in 2015). The data shall remain publicly accessible for at least three (3) years.

Audit Rights and Reconciliation of Expenses/Evaluation of Activity

The Applicant agrees to verify the manner in which the Grant is used. Within **ninety (90) days** of the completion



of the last activity described in the Grant Application, Applicant shall furnish: 1) a written statement verifying that the Project occurred; 2) a reconciliation of expenditures supported by the Grant as submitted in the Grant Application; and, 3) a final outcomes report or summary of the Project; 4) the aggregated summary results of the activity evaluations, if any.

Applicant must return to Biogen unexpended funds greater than one hundred (100) USD dollars, or any funds not utilized as stated and agreed upon, immediately. If Applicant fails to provide a timely reconciliation and/or fails to return any applicable unused funds, Applicant shall be ineligible to receive a decision on any pending requests until such reconciliation and/or return of funds has been received.

Upon reasonable advance notice, Applicant shall make available to Biogen and its designated representatives and regulatory agencies, during normal business hours, for the purpose of inspection, audit and reproduction, complete copies of financial and other records, including, but not limited to, receipts and invoices, documenting Applicant and each of their permitted subcontractors', expenses and costs related to the Project.

Publicity Rights

Applicant hereby grants permission to Biogen to publicly disclose all aspects of this Grant, including, but not limited to, the name of the Applicant and the Grant amount.

Biogen hereby grants permission to Applicant to disclose Biogen's role as a funder of this Grant, but Applicant agrees not to utilize Biogen's logo in any such disclosure and not to provide Biogen, in connection with this Grant, with any promotional benefits or forms of recognition that would typically be associated with sponsorship opportunities, as opposed to grants.

Data Privacy

In accordance with applicable data protection laws, Biogen processes Personal Data (meaning any information relating to an identified or identifiable natural person) you may provide to Biogen in order to fulfill and perform its obligations under this Agreement and also to comply with its legal obligations. Where necessary, Biogen may transfer Personal Data to other companies in its group and may also engage third party service providers (e.g. IT service providers) to process Personal Data you may provide on its behalf. Biogen will ensure that all recipients are contractually (e.g. by Standard Contractual Clauses) and/or legally obliged to comply with privacy standards in accordance with data protection law. These transfers may include transfers Biogen retains Personal Data you may provide for no longer than is necessary for the purposes for which it is collected. Data Subjects (as defined below) whose Personal Data you provide to Biogen may contact Biogen if they would like to access Personal Data you may provide or require information about the Personal Data that Biogen holds. They may object to the processing of the Personal Data for legitimate reasons and they may also request the correction or erasure of it. Some of these rights are limited by applicable data protection law and we have the right to collect, process and hold your personal data to perform our legal obligations. Should they feel it necessary, they also have the right to lodge a complaint with their data protection authority. If you have questions about our processing of Personal Data, you can contact Biogen's Global Privacy Office at privacy@biogen.com.

The Applicant's signature at the end of this Agreement represents his/her consent to the collection, processing and transmission of the Personal Data of the Applicant provided to Biogen, in compliance with applicable data protection laws.

"Data Subject" is a person who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person.

Terms & Terminations



This Agreement may be immediately terminated at any time by Biogen or the Applicant upon at least thirty (30) days advance written notice to the other Party in the event the other Party materially breaches this Agreement. In such event, the non-breaching Party shall notify the Party in breach of such breach in writing.

In the event, that the applicable legislation, jurisdiction or a Government authority decision, in accordance with the Applicant's country, could render this Agreement or any transaction based upon it being found a violation of applicable law or would otherwise have a material adverse effect on one of the Parties if the Agreement would remain in effect, each Party shall have the right to terminate this Agreement and rescind from or not fulfill any of its obligations.

Notwithstanding any liability of the Applicant under applicable law in case of termination by Biogen, Applicant will refund to Biogen the amount of Grant received by Biogen, unless Biogen instructs Applicant to refund a smaller amount. If any portion of the Grant has not been expended or allocated in accordance with the Project at the time of termination or expiration, the Applicant shall consult with Biogen to determine Biogen's wishes for an alternative use of the remaining portion.

Miscellaneous

This Agreement including any applicable appendices attached hereto as integral parts of this Agreement constitute the entire Agreement between the Parties with respect to the subject matter hereof and supersede all prior and contemporaneous oral, written and other Agreements between the Parties.

The rights and obligations of the Parties hereunder shall inure to the benefit of, and shall be binding upon, their respective successors and assigns. This Agreement may not be assigned by the Applicant without the prior written consent of Biogen. This Agreement may only be amended in writing, duly signed by the Parties hereto.

In the event any part of this Agreement shall be held illegal, void or ineffective, the remaining portions hereof shall remain in force and effect. If any of the terms or conditions of this Agreement are in conflict with any applicable laws or rules for professional conduct, then such terms or conditions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform to such laws or rules.

This Agreement constitutes the entire agreement between the Parties relating to the Grant and supersedes all other agreements, express or implied, between the Parties as to its subject matter. This Agreement may be modified only by a writing signed by both Parties which states it is an amendment to this Agreement. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, United States.

Counterparts

This Agreement (i) may be signed in counterparts, each of which shall constitute an original and all of which, taken together, shall constitute a single agreement binding on all Parties, and (ii) will be considered executed by a Party when the signature of such Party is delivered physically or by email or facsimile transmission to the other Party or Parties, as appropriate. The Parties agree that any signature delivered by email or facsimile transmission shall have the same force and effect as an original signature.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives as of the day and year last set forth below.

APPLICANT Fabrizio Tagliavivi Requesting@pganization's Authorized Signer

Name: ^{Fabrizio} Tagliavini



Letter of Agreement (LOA): Grant

Title: Dr Date: 02-apr-2021

BIOGEN

Biogen Representative

Name: Title: Date:

In Process



Certificato di completamento		
ID busta: FFB98ED233B7455DB96DB0653DAADC	3D	Stato: Inviato
Oggetto: 18431-P-FEL - Application Decision		
Vendor Name:		
Busta d'origine:		
Pagine documento: 7	Firme: 1	Creatore busta:
Pagine certificato: 5	Iniziali: 0	DARA CROCI
Firma guidata: Abilitato		225 Binney St
Timbro ID busta: Abilitato		Cambridge, MA 02142
Fuso orario: (UTC-05:00) Fuso orientale (USA e Ca	nada)	DARA.CROCI@BIOGEN.COM Indirizzo IP: 13.110.6.8
		Indin220 IF. 13.110.0.0
Verifica record		
Stato: Originale	Proprietario: DARA CROCI	Posizione: DocuSign
01/04/2021 13:35:29	DARA.CROCI@BIOGEN.COM	
Firmatario - Eventi	Firma	Timestamp
Fabrizio Tagliavini	DocuSigned by:	Inviato: 01/04/2021 13:36:26
ufficioricerca@istituto-besta.it	Fabrizio tagliavini	Visualizzato: 02/04/2021 11:35:23
Dr	F5F41757CFF64D6	Firmato: 02/04/2021 11:37:30
Livello di protezione: E-mail, Autenticazione accoun		
(nessuna)	Scelta della firma: Stile preselezionato	
	Mediante l'indirizzo IP: 93.39.105.196	
Record elettronico e divulgazione della firma: Accettato: 02/04/2021 11:35:23 ID: 9437f44d-c4d4-4bb6-aa68-a0e5cb9bd7bb		
Rachel McDonnell		Inviato: 02/04/2021 11:37:33
rachel.mcdonnell@biogen.com		
Director, Grants Management & Strategic Giving		
Biogen Livello di protezione: E-mail, Autenticazione accoun	t	
(nessuna) Record elettronico e divulgazione della firma:		
Non disponibile tramite DocuSign		
Firmatario di persona - Eventi	Firma	Timestamp
Editor - Eventi di recapito	Stato	Timestamp
Agente - Eventi recapito	Stato	Timestamp
Recapito intermedio - Eventi	Stato	Timestamp
Recapito consegna certificata - Eventi	Stato	Timestamp
Copia nascosta - Eventi	Stato	Timestamp
Firma come testimone gli eventi	Firma	Timestamp

Riepilogo busta - Eventi

Pubblico ufficiale - Eventi

Busta inviata

Con hash/Crittografato

Firma

Stato

01/04/2021 13:36:26

Timestamp

Data e ora

Eventi di pagamento	Stato	Data e ora
Record elettronico e divulgazione della firma		

In Process

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Biogen (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through your DocuSign, Inc. (DocuSign) Express user account. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the 'I agree' button at the bottom of this document.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. For such copies, as long as you are an authorized user of the DocuSign system you will have the ability to download and print any documents we send to you through your DocuSign user account for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of your DocuSign account. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use your DocuSign Express user account to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through your DocuSign user account all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Biogen:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: DL-eSignature@biogen.com

To advise Biogen of your new e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at DL-eSignature@biogen.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address. In addition, you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

To request paper copies from Biogen

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to DL-eSignature@biogen.com and in the body of such request you must state your e-mail address, full name, Postal address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Biogen

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your DocuSign account, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may; ii. send us an e-mail to DL-eSignature@biogen.com and in the body of such request you must state your e-mail, full name, IS Postal Address, telephone number, and account number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Operating Systems:	Windows2000? or WindowsXP?
Browsers (for SENDERS):	Internet Explorer 6.0? or above
Browsers (for SIGNERS):	Internet Explorer 6.0?, Mozilla FireFox 1.0,
	NetScape 7.2 (or above)
Email:	Access to a valid email account
Screen Resolution:	800 x 600 minimum
Enabled Security Settings:	
	•Allow per session cookies
	•Users accessing the internet behind a Proxy
	Server must enable HTTP 1.1 settings via
	proxy connection

Required hardware and software

** These minimum requirements are subject to change. If these requirements change, we will provide you with an email message at the email address we have on file for you at that time providing you with the revised hardware and software requirements, at which time you will have the right to withdraw your consent.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I Agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF • ELECTRONIC RECORD AND SIGNATURE DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can • print it, for future reference and access; and
- Until or unless I notify Biogen as described above, I consent to receive from • exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by Biogen during the course of my relationship with you.